profit from every $100 of sales.
$0$100
Insulet
$152.48+2.14% today
-54.2% in 1 year
1-year low $130.471-year high $346.36
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $42.81 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Insulet sold, what it kept, and what it did with the cash.
Sales went from $1.31 billion in 2022 to $2.71 billion in 2025, with $247 million of profit last year.
SalesProfit
Insulet handed back 17% of the cash it generated last year.
Buybacks $60M
Free cash flow 2025$350M
Bought back its own shares$60M
Paid as dividends–
Cash vs. debt$716M vs. $949M
Insulet vs. similar companies
Insulet grows the fastest of these 5 and is priced in the middle for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Insulet | 42.8× · Expensive | ||
 Abbott Laboratories | 28.8× · Fair price | ||
 Medtronic | 27.4× · Fair price | ||
 Stryker | 36.3× · Expensive | ||
 Edwards Lifesciences | 57.4× · Expensive |
AI analysis
An AI analyst reads Insulet's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 904 | 1,099 | 1,305 | 1,697 | 2,072 | 2,708 | |
| 582 | 752 | 806 | 1,160 | 1,446 | 1,940 | |
| 52 | 126 | 38 | 220 | 309 | 474 | |
| 113 | 140 | 109 | 324 | 424 | 489 | |
| 7 | 17 | 5 | 206 | 418 | 247 | |
| 0.10 | 0.24 | 0.07 | 2.94 | 5.78 | 3.48 | |
| 64.4% | 68.4% | 61.7% | 68.3% | 69.8% | 71.6% | |
| 5.7% | 11.5% | 2.9% | 13.0% | 14.9% | 17.5% | |
| 0.8% | 1.5% | 0.4% | 12.2% | 20.2% | 9.1% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 1,873 | 2,049 | 2,251 | 2,588 | 3,088 | 3,190 |
| Cash | 907 | 806 | 674 | 704 | 953 | 716 |
| Total debt | 1,059 | 1,274 | 1,402 | 1,416 | 1,380 | 949 |
| Total liabilities | 1,269 | 1,493 | 1,775 | 1,856 | 1,876 | 1,675 |
| 604 | 556 | 476 | 733 | 1,212 | 1,515 | |
| 66 | 69 | 70 | 74 | 74 | 72 | |
| 2.7% | 3.5% | 1.9% | 9.2% | 10.5% | 12.8% | |
| 1.1% | 3.0% | 1.0% | 28.2% | 34.5% | 16.3% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 84 | -68 | 119 | 146 | 430 | 569 | |
| – | – | 157 | 109 | 134 | 219 | |
| – | – | -38 | 37 | 296 | 350 | |
| Dividends paid | – | – | – | – | – | – |
| – | – | – | 0 | 0 | 60 | |
| 36 | 34 | 41 | 48 | 69 | 63 |
Valuation
- 42.8×
- –
- 0.41
- 6.9×
- 3.9×
- 30.2×
- 22.1×
- 3.3%
- 2.3%
- 0.0%
Profitability
- 71.6%
- 17.5%
- 9.1%
- 19.4%
- 13.1%
- 8.8%
- 21.4%
- 10.1%
- 22.1%
- 11.4%
Growth
- +24.5%
- +103.4%
- +23.7%
- –
- +0.9%
Financial health
- 0.5×
- 0.63
- 31.7%
- 6.7×
- 2.81
- 1.81
- 0.97
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 19%of 964
Top 32%of 898
Bottom 29%of 651
Top 21%of 911
Top 36%of 991
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | 1.42 | 1.19 | +19.3% |
| Feb 18, 2026 | 1.55 | 1.47 | +5.4% |
| Nov 6, 2025 | 1.24 | 1.14 | +8.8% |
| Aug 7, 2025 | 1.17 | 0.92 | +27.2% |
| May 8, 2025 | 1.02 | 0.79 | +29.1% |
| Feb 20, 2025 | 1.15 | 1.00 | +15.0% |
| Nov 7, 2024 | 0.90 | 0.76 | +18.4% |
| Aug 8, 2024 | 0.55 | 0.56 | −2.5% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
51No pass
Benjamin Graham
42No pass
Philip Fisher
70Pass
Peter Lynch
93Pass
Joel Greenblatt
15No pass
Charlie Munger
51No pass
Terry Smith
57No pass
Questions about Insulet
Is Insulet a good stock to buy?
A solid business, but the price is high. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Insulet AI analysis
What does Insulet do?
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. It is in Medical Devices, based in Acton, MA, United States, with 5,400 employees.
Does Insulet pay a dividend?
No. Insulet does not pay a dividend at the moment; in 2025 it returned $59.6 million to shareholders by buying back its own shares.
Is Insulet stock halal?
Yes. Insulet passes our halal screen: its business is permitted and its debt is 9% of its market value, under the 30% limit. How we check
How has Insulet stock done over the past year?
Down 54.2% over the past twelve months, to $152.48. It traded between $130.47 and $346.36 and is 56.0% below its high.
Who are Insulet's competitors?
The largest listed companies in the same industry are Abbott Laboratories, Medtronic, Stryker and Edwards Lifesciences. The peers table on this page compares their profit, growth and price with Insulet's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.